Monday's top analyst upgrades, downgrades and initiations include AbbVie, Alcoa, Apple, Deckers Outdoor, Dish Network, Pfizer and Petrobras.
If there is one thing that the pharmaceutical industry tries to shy away from it is the controversy over the costs of some of the drugs on the market today.
Tuesday after the U.S. markets close, Gilead Sciences will report its fourth-quarter financial results.
AbbVie reported better-than-expected fourth-quarter financial results Friday before the markets open.
Chris Lange Gilead Sciences was picked up by Anthem to provide its hepatitis C drug as the primary option for patients.
Is it possible that Gilead Sciences is already coming back into favor after just a week of being in the doghouse?
Analysts are beginning to make their calls for what the future will hold for Gilead Sciences, AbbVie and Express Scripts.
AbbVie and Express Scripts have entered into an exclusive agreement under which Express Scripts will distribute AbbVie's hepatitis treatment.
Thursday's top analyst upgrades and downgrades from 24/7 Wall St. include ARIAD Pharmaceuticals, FedEx, Genpact, Suncor Energy, Travelers and UPS.
Friday's top analyst upgrades, downgrades and initiations include Harley-Davidson, Lululemon, Nike, SunPower and Walmart.
A new research report from the analysts at UBS focuses on four companies that stand to benefit from rising demand for the drugs they produce that treat hepatitis C.
Only one of the seven stocks traded on the New York Stock Exchange with the largest number of shares held short as of October 15 experienced a decline in short interest.
UBS polled all of its analysts, who came up with 26 stocks by now. Here are the ones that offer large cap growth with the best upside.
The most shorted stocks on the New York Stock Exchange at the September 30 settlement dates saw rising short interest during the two-week period.
Short sellers shied away from Bank of American enough that it slipped out of the top five most shorted stocks on the New York Stock Exchange.
